Bullous Pemphigoid

For a patient with tense bullae, erosions, or a persistent pruritic urticarial or eczematous eruption suspicious for BP, obtain a perilesional biopsy for direct immunofluorescence (DIF). Sample erythematous perilesional skin rather than the bulla itself and place the specimen in Michel medium. A supportive pattern is linear IgG and/or C3 at the dermoepidermal junction. PubMedPubMedNavigating Bullous Pemphigoid: Consensus Recommendations for ...

Order serum anti-BP180 and anti-BP230 IgG ELISAs and consider indirect immunofluorescence (IIF), particularly on salt-split skin, at initial evaluation. In one comparative study, DIF sensitivity was 90.8% and specificity 98%; combined serologic testing had 88.8% sensitivity. Thus, a negative BP180 or BP230 ELISA alone should not overrule a compatible clinical presentation or a positive DIF. PubMedPubMedComparative study of direct and indirect immunofluorescence and of bullous pemphigoid 180 and 230 enzyme-linked immunosorbent assays for diagnosis of bullous pemphigoid. - Abstract

Salt-split IIF is most useful when DIF or ELISA findings are discordant with morphology or when another autoimmune subepidermal blistering disorder remains plausible. Reported specificity for salt-split IIF was 99.9%, while BP180 NC16A ELISA sensitivity and specificity were 70.0% and 89.8%, respectively, in a consensus evidence summary. PubMedPubMedNavigating Bullous Pemphigoid: Consensus Recommendations for ...

Document extent of blisters and erosions, active urticarial or eczematous inflammation, itch severity, mucosal involvement, and functional effects before treatment. BPDAI erosion/blister, urticaria/erythema, mucosal, and itch measures were responsive to therapy in a retrospective treatment comparison and can provide a reproducible baseline for subsequent reassessment. ScienceDirectScienceDirectDupilumab, corticosteroids and their combination for the treatment of bullous pemphigoid - ScienceDirect

Perform a medication review at diagnosis. DPP-4 inhibitor labeling includes bullous pemphigoid among recognized warnings and precautions for saxagliptin-containing products; a temporally plausible exposure should be identified as a potentially modifiable contributor while diagnostic confirmation proceeds. fdafda[PDF] Clinical Review: Onglyza (saxagliptin)/Kombiglyze XR (saxagliptin ...

Weigh systemic corticosteroid exposure particularly carefully in older or medically complex patients. Long-term high-dose systemic corticosteroids contribute to increased morbidity and mortality, with recognized risks including severe infection, hyperglycemia, hypertension, osteoporosis, myopathy, neurocognitive effects, thromboembolic complications, and gastrointestinal ulceration. ScienceDirect+1ScienceDirectImmunosuppressive therapy for autoimmune bullous diseasesOxford AcademicTreatment of bullous pemphigoid with methotrexate is associated ...

Use mucosal disease as an escalation signal. In a retrospective study of dupilumab, BPDAI mucosal scores did not significantly improve despite improvement in other clinical measures; persistent mucosal involvement therefore warrants prompt reassessment of diagnosis and treatment adequacy rather than assuming cutaneous response establishes full control. ScienceDirectScienceDirectDupilumab, corticosteroids and their combination for the treatment of bullous pemphigoid - ScienceDirect

For patients requiring prompt control, prednisolone 0.5 mg/kg/day achieved disease control at 6 weeks in 91% of participants in a randomized trial, compared with 74% for doxycycline 200 mg/day. The adjusted difference was 18.6 percentage points, favoring prednisolone for short-term effectiveness. The LancetThe LancetDoxycycline: a first-line treatment for bullous pemphigoid? - The Lancet

Doxycycline 200 mg/day is a reasonable initial lower-toxicity strategy when slower or less complete early control is acceptable and systemic corticosteroid harm is a dominant concern. In the same randomized comparison, the key tradeoff was lower 6-week control than prednisolone, while the study was designed to assess whether doxycycline reduced severe treatment-related adverse effects. The LancetThe LancetDoxycycline: a first-line treatment for bullous pemphigoid? - The Lancet

For adults with BP, dupilumab is FDA labeled as a 600 mg subcutaneous loading dose followed by 300 mg subcutaneously every 2 weeks. The label directs use with a tapering course of oral corticosteroids; after disease control, gradually taper corticosteroids and continue dupilumab monotherapy. Add corticosteroids again for relapse if medically advisable. accessdata fda+1accessdata fda[PDF] Page 1 of 77 - accessdata.fda.govaccessdata fda[PDF] DUPIXENT® (dupilumab) injection, for subcutaneous use

Dupilumab should not be positioned as a guarantee of immediate remission. In a retrospective cohort of 146 patients, 127 patients (87%) achieved disease control within 4 weeks, while 8 patients (5.5%) reached disease control after 4 weeks. Use active disease tracking during the first month to identify continued blistering that requires treatment reassessment. JAMAJAMAEvaluation of Dupilumab in Patients With Bullous Pemphigoid

At each early follow-up, document new blisters and erosions, healing of prior erosions, urticarial or eczematous activity, itch, and mucosal involvement using the same baseline measures. In dupilumab-treated patients, BPDAI total, erosion/blister, urticaria/erythema, and itch scores improved within 2 to 4 weeks in one retrospective study, making this interval a pragmatic window for verifying a directional response. ScienceDirectScienceDirectDupilumab, corticosteroids and their combination for the treatment of bullous pemphigoid - ScienceDirect

If disease remains active beyond the expected early control interval, first verify diagnosis and treatment execution: review DIF site quality, BP180/BP230 results, and whether salt-split IIF is needed. Then reassess corticosteroid risk, ongoing medication exposures, mucosal disease, and whether escalation to a steroid-sparing regimen is warranted. PubMed+2PubMedComparative study of direct and indirect immunofluorescence and of bullous pemphigoid 180 and 230 enzyme-linked immunosorbent assays for diagnosis of bullous pemphigoid. - AbstractPubMedDiagnostic values of indirect immunofluorescence using salt-split skin, direct immunofluorescence and BP180 NC16A ELISA on bullous pemphigoid - PMCPubMedNavigating Bullous Pemphigoid: Consensus Recommendations for ...

For dupilumab-treated adults, taper oral corticosteroids only after disease control and continue dupilumab monotherapy thereafter per labeling. If relapse occurs, oral corticosteroids may be re-added when medically advisable; this is a treatment decision requiring renewed assessment of cumulative steroid harm. accessdata fda+1accessdata fda[PDF] Page 1 of 77 - accessdata.fda.govaccessdata fda[PDF] DUPIXENT® (dupilumab) injection, for subcutaneous use

For difficult-to-control disease, biologic approaches beyond dupilumab have been reported, including rituximab, omalizumab, and mepolizumab, but the evidence base summarized in systematic reviews is heterogeneous. Rituximab reports include infection and septicemia among serious adverse events in autoimmune bullous disease cohorts; reserve such approaches for specialist-directed management after confirmation of the disease category and careful infection-risk assessment. ScienceDirect+2ScienceDirectImmunosuppressive therapy for autoimmune bullous diseasesWileyEfficacy and safety of biological agents for pemphigoid: a systematic review and meta‐analysis - Lin - 2023 - International Journal of Dermatology - Wiley Online LibraryScienceDirectExacerbation of bullous pemphigoid after hand, foot, and mouth disease treated with rituximab